RxDoctor Payments Data

Stephanie Badon, APRN

Psychiatric/Mental Health · Youngsville, LANPI 1649936956

Payments from drug & device makers

$3,231in general payments, 2019–2025

Across 213 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$601
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$514
  • Alkermes, Inc.$448
  • Otsuka America Pharmaceutical, Inc.$311
  • Johnson & Johnson$287
  • Teva Pharmaceuticals USA, Inc.$209
  • plus $861 from 13 others

What the payments were for

  • Food & beverage$3,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,231 in reported general payments places this provider in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,727
Medicare patients
12
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate89$286,499
LatudaLurasidone Hcl12$27,754
CaplytaLumateperone Tosylate16$27,675
LybalviOlanzapine/Samidorphan Malate18$27,480
Lurasidone Hcl24$3,524
Quetiapine Fumarate162$1,552
Buspirone Hcl121$1,545
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine66$1,514
Olanzapine47$1,310
Divalproex Sodium ErDivalproex Sodium44$1,295
Aripiprazole32$1,271
Hydroxyzine Pamoate63$1,251
Clonazepam124$1,210
Oxcarbazepine49$1,192
Clomipramine Hcl12$1,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$287$286,49989 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$514$27,67516 claims
Alkermes, Inc.Lybalvi$448$27,48018 claims
Teva Pharmaceuticals USA, Inc.Loxapine$209$82221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Youngsville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →